Tricuspid regurgitation — chronic management
Right-sided valve disease · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Tricuspid regurgitation is most often secondary (functional) from annular dilatation and right-ventricular remodelling, frequently linked to left-heart disease, atrial fibrillation or pulmonary hypertension. Severe disease causes right heart failure and benefits from earlier recognition and intervention.
Red flags
- Refractory ascites and peripheral oedema
- Progressive right heart failure
- Cardiac cachexia
- Worsening hepatic/renal function from congestion
- Severe TR with declining RV function
Assessment
Differential diagnosis
- Secondary (functional) TR
- Primary TR (endocarditis, rheumatic, carcinoid, device-lead)
- Right heart failure of other cause
- Constrictive pericarditis
- Ebstein anomaly
- Hepatic congestion of non-cardiac origin
Investigations
- Transthoracic echo (TR severity, annular size, RV function)
- Transoesophageal echo for valve morphology and intervention planning
- ECG (atrial fibrillation, RV strain)
- Right-heart catheterisation for pulmonary pressures
- Liver function and congestion markers
- Cardiac CT/MRI for RV volumes and procedural planning
Management
- Grade severity and determine whether primary or secondary
- Identify and treat drivers: left-heart disease, pulmonary hypertension, atrial fibrillation
- Optimise diuretic therapy for congestion
- Treat atrial fibrillation (rhythm/rate control) which worsens functional TR
- Address left-sided valve lesions — improving them often improves TR
- Refer severe primary TR for surgical repair/replacement before RV failure develops
- Consider concomitant tricuspid repair during left-sided valve surgery when the annulus is dilated
- Assess transcatheter tricuspid intervention for high-surgical-risk symptomatic severe secondary TR
- Monitor RV function and avoid operating too late
- Manage hepatic and renal consequences of chronic congestion
- Provide anticoagulation if atrial fibrillation present
- Arrange structured valve-clinic follow-up
Drugs & doses
Furosemide 40-120 mg PO OD (or bumetanide 1-5 mg OD) for congestion
Spironolactone 25-50 mg PO OD (aldosterone antagonism, congestion)
Apixaban 5 mg PO BD if atrial fibrillation present
Treat underlying left-heart failure with guideline-directed therapy
Disposition
Refer to a heart-valve multidisciplinary team; surgical or transcatheter intervention for severe symptomatic disease. Valve-clinic surveillance otherwise.
Complications & pitfalls
- Right ventricular failure
- Hepatic congestion and cardiac cirrhosis
- Renal dysfunction (cardiorenal)
- Atrial arrhythmias
- Poor surgical outcomes if intervention delayed
Exam pearls
- Isolated late tricuspid surgery after prior left-heart surgery carries high risk — address TR earlier
- Treating atrial fibrillation and left-heart disease often improves functional TR
- Transcatheter tricuspid therapies are expanding options for high-risk patients
- Severe TR is frequently under-recognised and under-treated
- Right ventricular failure, once advanced, limits reversibility
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.